Self-expandable stenting with jailed deep femoral artery (DFA) for proximal superficial femoral artery (SFA) lesions is safe

Original title: Deployment of Self-Expandable Stents for Complex Proximal Superficial Femoral Artery Lesions Involving the Femoral Bifurcation With Or Without Jailed Deep Femoral Artery. Reference: Masahiro Yamawaki et al. Catheterization and Cardiovascular Interventions 81:1031–1041 (2013).

The endovascular management of chronic total occlusions of the lower extremities has seen great progress over the past years; however, specific segments require further consideration. Endovascular treatment of ostial lesions of the superficial femoral artery compromising the common superficial and deep femoral bifurcation requires further consideration. This segment has been systematically excluded from randomized studies that compare balloon angioplasty vs. stenting because jailed deep femoral artery after distal stenting is not considered safe, which results in the prevalence of surgery as preferred option.

The aim of this study was to compare the safety and efficacy of self expandable stenting with jailed DFA, vs. ostial SFA stenting. The FB (femoral bifurcation) was defined as the segment beginning in the distal CFA, 10 mm proximal to the DFA ostium and ending in the SFA and 10 mm distal to the carina. 104 consecutive, de novo lesions involving the SFA ostium were included: 60 (57.7%) distal common femoral artery (CFA) stenting with jailed DFA and 44 (43.3%) ostial SFA stenting without jailed DFA.

At 12 months follow up, bifurcation patency was higher after distal CFA stenting with jailed DFA (83.3% vs. 56.3%; P < 0.01). In the same period, though not significantly, primary patency was also higher. Globally, repeat revascularization at 12 months was 34.2% (28.9% percutaneous and 5.4% surgical). 

Conclusion: 

Patency after self-expandable stenting with jailed deep femoral artery (DFA) for proximal superficial femoral artery (SFA) lesions was acceptable and was also associated with higher bifurcation patency when compared to ostial SFA stenting. 

Editorial Comment: 

When treating the compromised femoral bifurcation, given the success of endarterectomy and patch angioplasty, both the center where this study was carried out and the current guidelines are for the surgical management; this is why all patients included in this study were either non surgical or had simply refused surgery. Endovascular management of CFA is usually avoided in this highly mobile area because of the risk of stent fracture, pain or thrombosis. The fact that lesions are not completely covered probably explains the lower patency of ostial SFA stenting. 

SOLACI.ORG

More articles by this author

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...

IVUS-Guided vs. Angiography-Guided Drug-Coated Balloon Angioplasty in the Treatment of Femoropopliteal Lesions

Angiography has traditionally been the primary imaging technique for endovascular therapy guidance in patients with peripheral artery disease. However, as it only provides two-dimensional...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...